A. Linauskas

发表

FRI0067 Changes in Multi-Biomarker Disease Activity (MBDA) Score Correlate with Changes in Established Disease Activity Measurements in Patients with Early Ra from The Opera Study

C. Brahe, P. Junker, N. Defranoux, 2016 .

Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

Pall I. Olason, H. Stefánsson, D. Gudbjartsson, 2022, Annals of the Rheumatic Diseases.

Positive predictive value of first-time rheumatoid arthritis diagnoses and their serological subtypes in the Danish National Patient Registry

K. Overvad, K. Stengaard-Pedersen, A. de Thurah, 2018, Clinical epidemiology.

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial

C. Brahe, K. Stengaard-Pedersen, T. Ellingsen, 2018, Scandinavian journal of rheumatology.

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

M. Østergaard, K. Stengaard-Pedersen, H. C. Horn, 2014, Annals of the rheumatic diseases.

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

M. Østergaard, K. Stengaard-Pedersen, H. C. Horn, 2013, Annals of the rheumatic diseases.

FRI0190 Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up. results from the danbio registry

B. Glintborg, M. Hetland, S. Chrysidis, 2017 .

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

A. Loft, I. Hansen, B. Glintborg, 2017, Annals of the rheumatic diseases.

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)

M. Østergaard, K. Stengaard-Pedersen, T. Ellingsen, 2015, Annals of the rheumatic diseases.

Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab—a substudy of the optimized treatment algorithm in early RA (OPERA) trial

H. Bliddal, K. Stengaard-Pedersen, H. C. Horn, 2017, Clinical Rheumatology.

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

K. Stengaard-Pedersen, H. C. Horn, T. Ellingsen, 2015, The Pharmacogenomics Journal.

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

A. Loft, J. K. Pedersen, F. Mehnert, 2022, RMD Open.

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

A. Loft, I. Hansen, F. Mehnert, 2018, Annals of the rheumatic diseases.

Body Fat Percentage, Waist Circumference, and Obesity As Risk Factors for Rheumatoid Arthritis: A Danish Cohort Study

D. Symmons, K. Overvad, K. Stengaard-Pedersen, 2019, Arthritis care & research.

Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study

H. Leffers, A. Voss, L. Dreyer, 2021, Lupus Science & Medicine.

One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept: – an Observational Study from the Danish Danbio Registry

A. Loft, I. Hansen, B. Glintborg, 2017 .

Identification of Etanercept Responsive Biomarkers in Rheumatoid Arthritis

A. Stensballe, A. Linauskas, Ditte Bech Laursen, 2020 .

Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA)

M. Østergaard, K. Stengaard-Pedersen, T. Ellingsen, 2015, Annals of the rheumatic diseases.

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

A. Loft, I. Hansen, B. Glintborg, 2017, Annals of the rheumatic diseases.

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

M. Østergaard, K. Stengaard-Pedersen, H. C. Horn, 2013, Annals of the rheumatic diseases.